Implication of Unfavorable Histology, MYCN Amplification and Diploidy for Stage I and II Neuroblastomas

Abstract

Background: Surgery is the first line treatment for low-grade neuroblastomas. In stage I tumors, the presence of MYCN amplification is rarely detected and the Shimada histology is not always taken into consideration when deciding on the treatment. This study concerns the significance of these two factors in the evolution of children with low-grade neuroblastomas. Methods: We analyzed the assessment and follow-up of children with low-grade neuroblastomas (stages I and II) with or without MYCN amplification, with either a favorable or unfavorable histology and with or without tumor cell diploidy. Favorable histology was defined as stroma-poor tumors with more than 5 % differentiating neuroblasts and a mitosis karyorrhexis index (MKI) of less than 100/5000 cells. Results: From 1995 to 2006, out of 114 neuroblastomas, nine (7.9 %) were stage I and 21 (18.4 %) stage II. Of these 30 patients, 27 underwent surgery alone and three received chemotherapy after surgery. The combination of MYCN amplification, unfavorable histology and diploidy was noted in one patient who developed metastases within two months. MYCN amplification alone was noted in two cases who are still tumor-free after two years. Unfavorable histology alone was noted in four patients, of whom one suffered a recurrence of the tumor (previously stage I) and three are tumor-free after six years. Tumor cell diploidy alone was present in 11 patients whose evolution is satisfactory. Conclusion: Because MYCN amplification and unfavorable histology are rare in early stage neuroblastomas, these tumors may be misclassified if they are not investigated further. It seems that no single clinical or biological feature can be considered a significant factor in establishing a prognosis or determining whether additional treatment is required.

Key words

neuroblastoma - MYCN amplification - histology - diploidy

References

• 1 Alvarado C S, London W B, Look A T. et al . Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group study.  J Pediatr Hematol Oncol. 2000;  22 197-205
• 2 Andersen B D, Schoenfeld M, Chesen B D. Current clinical trials in neuroblastoma.  Oncology. 2002;  16 82-89
• 3 Brodeur G M, Pritchard J, Berthold F. et al . Revisions of the international criteria for neuroblastoma diagnosis, staging, and responses to treatment.  J Clin Oncol. 1993;  11 1466-1477
• 4 Cohn S L, Look A T, Joshi V V. et al . Lack of correlation of MYCN gene amplification with prognosis in localized neuroblastoma. A Pediatric Oncology Group study.  Cancer Res. 1995;  55 721-726
• 5 Cohn S L, Tweddle D A. MYCN amplification remains prognostically strong 20 years after its clinical debut.  Eur J Cancer. 2004;  40 2639-2642
• 6 Evans A R, Brand W, de Lorimier A. et al . Results in children with local and regional neuroblastoma managed with and without vincristine, cyclophosphamide, and imidazolecarboxamide: a report from the Children's Cancer Study Group.  Am J Clin Oncol. 1984;  7 3-7
• 7 Evans A E, D'Angio G J, Randolph J. A proposed staging for children with neuroblastoma: Children's Cancer Study Group A.  Cancer. 1971;  27 374-378
• 8 Fabbretti G, Valenti C, Loda M. et al . MYCN gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma).  Hum Pathol. 1993;  24 294-297
• 9 Hann H W, Evans A E, Siegel S E. et al . Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: the Children's Cancer Study Group experience.  Cancer Res. 1985;  45 2843-2848
• 10 Ishola T A, Chung D H. Neuroblastoma.  Surgical Oncology. 2007;  16 149-156
• 11 Look A T, Hayes F A, Shuster J J. et al . Clinical relevance of tumor cell ploidy and MYCN gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.  J Clin Oncol. 1991;  9 581-591
• 12 Miller M A, Ohashi K, Zhu X. et al . Survin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the Children's Oncology Group.  J Pediatr Hematol Oncol. 2006;  28 412-417
• 13 Perez C A, Matthay K K, Atkibson J B. et al . Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study.  J Clin Oncol. 2000;  18 18-26
• 14 Rubie H, Hartmann O, Michon J. et al . MYCN gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 Study-Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique.  J Clin Oncol. 1997;  15 1171-1182
• 15 Seeger R C, Brodeur G M, Sather H. et al . Association of multiple copies of the MYCN oncogene with rapid progression of neuroblastomas.  N Engl J Med. 1985;  313 1111-1116
• 16 Schneidermann J, London W B, Brodeur G M. et al . Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.  J Clin Oncol. 2008;  26 913-918
• 17 Shimada H, Chatten J, Newton W A. et al . Definition of subtypes of ganglioneuroblastoma and age-linked classification of neuroblastomas.  J Natl Cancer Inst. 1984;  73 405-416
• 18 Shimada H, Umehara S, Monobe Y. et al . International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors.  Cancer. 2001;  92 2451-2461
• 19 Shuster J J, McWilliams N B, Castelberry R. et al . Serum lactate dehydrogenase in childhood neuroblastoma: a Pediatric Oncology Group recursive partitioning study.  Am J Clin Oncol. 1992;  15 295-303
• 20 Silber J H, Evans A E, Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology.  Cancer Res. 1991;  51 1426-1433
• 21 Slack A, Chen Z, Tonelli R. et al . The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.  Proc Natl Acad Sci USA. 2005;  102 731-736
• 22 Spitz R, Betts D R, Simon T. et al . Favorable outcome of triploid neuroblastoma. A contribution to the special oncogenesis of neuroblastoma.  Cancer Gen Cyto. 2006;  167 51-56
• 23 Tajiri T, Higashi M, Souzaki R. et al . Classification of neuroblastoma based on an analysis of the expression of genes related to prognosis.  J Pediatr Surg. 2007;  42 2046-2049